source
- Caldera Therapeutics merges with Synlogic, secures $278M to advance inflammation drugCaldera Therapeutics, a startup founded seven months ago with $112.5 million of venture funding, announced a merger with Synlogic, a company that previously went public via a reverse merger. The a…
- MapLight's schizophrenia drug fails primary endpoint in Phase 2, sending stock down over 60%MapLight Therapeutics saw its shares tumble more than 60% after a mid‑stage trial showed that its once‑daily schizophrenia candidate did not meet the primary efficacy endpoint, even though the over…